REGENXBIO Announces Pricing of Initial Public Offering
September 16, 2015
ROCKVILLE, Md. — REGENXBIO Inc. (“REGENXBIO”), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. In addition, REGENXBIO granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on September 17, 2015 under the ticker symbol “RGNX.”
Morgan Stanley and BofA Merrill Lynch are acting as active joint book-running managers of the proposed offering. Piper Jaffray is acting as a passive book-running manager. Chardan Capital Markets is acting as a co-manager.
This offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at firstname.lastname@example.org.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 16, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. REGENXBIO’s NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed candidates and 18 partnered candidates developed by REGENXBIO’s licensees.
Elizabeth Broder, 646-378-2945
Laura Bagby, 312-448-8098